29th Annual Swiss Symposium in Pharmaceutical Medicine 2024
27th November 2024
Musikschule, Florhofgasse 6, Zurich
27th November 2024
Musikschule, Florhofgasse 6, Zurich
Special Populations in Drug Development and Clinical Care:
Across the Entire Life Spanfrom Paediatrics to Geriatrics
Chairs: Antonio Amodeo, CTC, Zürich, and representative from industry
The 29th Annual Swiss Symposium in Pharmaceutical Medicine will be organised by the Swiss Society of Pharmaceutical Medicine (SGPM) in partnership with and scientific support from the European Center of Pharmaceutical Medicine (ECPM).
With a keen focus on Vulnerable Populations, the symposium promises an insightful keynote address elucidating the Ethical Aspects inherent in addressing their unique healthcare needs. Delving deeper, sessions will delve into the intricacies of Developmental Pharmacology and Pharmacometrics, offering strategies to advance Neonatal and Paediatric Drug Development, alongside comprehensive discussions on Clinical Trials in Children, featuring insights from Swissmedic, the Swiss Agency for Therapeutic Products.
The focus of this symposium lies on Vulnerable Populations and Ethical Aspects of such populations will be discussed in a key-note speech following the welcome addresses. There will be presentations on Developmental Pharmacology and Pharmacometrics to Facilitate Neonatal and Paediatric Drug Development as well as on Clinical Trials in Children. Swissmedic, the Swiss Agency for Therapeutic Products, has been requested to provide a speaker for a talk on Regulatory Aspects of Clinical Trials in Children.
Gender Pharmacology will be addressed as well as a Case Study about the Use in Multiple Sclerosis during Pregnancy and a presentation on the Inclusion of Geriatric Populations in Clinical Trials.
Galenical Considerations and Application Systems for Paediatricand Geriatric Patients will be presented and also Nutrigenomics; Interventions for the Ageing Population.The final talk will be on Legal Considerations of Clinical Testing in Vulnerable Populations.
Across the Entire Life Spanfrom Paediatrics to Geriatrics
Chairs: Antonio Amodeo, CTC, Zürich, and representative from industry
The 29th Annual Swiss Symposium in Pharmaceutical Medicine will be organised by the Swiss Society of Pharmaceutical Medicine (SGPM) in partnership with and scientific support from the European Center of Pharmaceutical Medicine (ECPM).
With a keen focus on Vulnerable Populations, the symposium promises an insightful keynote address elucidating the Ethical Aspects inherent in addressing their unique healthcare needs. Delving deeper, sessions will delve into the intricacies of Developmental Pharmacology and Pharmacometrics, offering strategies to advance Neonatal and Paediatric Drug Development, alongside comprehensive discussions on Clinical Trials in Children, featuring insights from Swissmedic, the Swiss Agency for Therapeutic Products.
The focus of this symposium lies on Vulnerable Populations and Ethical Aspects of such populations will be discussed in a key-note speech following the welcome addresses. There will be presentations on Developmental Pharmacology and Pharmacometrics to Facilitate Neonatal and Paediatric Drug Development as well as on Clinical Trials in Children. Swissmedic, the Swiss Agency for Therapeutic Products, has been requested to provide a speaker for a talk on Regulatory Aspects of Clinical Trials in Children.
Gender Pharmacology will be addressed as well as a Case Study about the Use in Multiple Sclerosis during Pregnancy and a presentation on the Inclusion of Geriatric Populations in Clinical Trials.
Galenical Considerations and Application Systems for Paediatricand Geriatric Patients will be presented and also Nutrigenomics; Interventions for the Ageing Population.The final talk will be on Legal Considerations of Clinical Testing in Vulnerable Populations.
Impressions of the last years
